Glucotrack, Inc. (GCTK) · Oct 28, 2026 · Other events

Glucotrack reverse split confirms Lokahi control, adds debt detail

1-for-2 reverse split — Shares reduced from 2,368,237 to approximately 1,184,119

Glucotrack’s reverse split is now reflected in the filings, but the pro forma merger details highlight Lokahi control, bridge debt, and financing strain.

Glucotrack now sits behind a Lokahi-controlled clinical-stage biotechnology platform, while its legacy business remains an implantable continuous glucose monitor subsidiary. The reverse split itself changes the share count, not the business. The 1-for-2 split became effective October 23, 2026, began trading on a split-adjusted basis October 26, and left authorized shares unchanged at 250 million. 〔0〕 The company says shares outstanding fell from 2,368,237 to approximately 1,184,119, with proportional adjustments to options and warrants. 〔1〕 Because the split was already approved and effective before this filing, this is confirmation rather than a fresh strategic event.

Pro forma combined figureAmountFiling context
Cash and cash equivalents$10.6MJune 30, 2026 pro forma balance sheet
Total liabilities$25.3MJune 30, 2026 pro forma balance sheet
Convertible notes at fair value$11.7MBridge financings
In-process R&D and other identified intangibles$25.4MLokahi purchase-price allocation
Goodwill$15.6MLokahi purchase-price allocation
Aggregate merger consideration$34.3M2,738,408 common-equivalent shares

The filing’s more meaningful signal is the capital structure behind the pivot. Former Lokahi holders collectively receive 90% of the combined company’s equity, while the pro forma balance sheet carries $11.7 million of convertible notes and $1.1 million of warrant liabilities. 〔2〕 That makes this economically a Lokahi-led platform with Glucotrack’s legacy CBGM business retained inside it, not simply a clean continuation of the glucose-monitor story.

The financing buys runway but at a heavy cost. The two bridge financings generated $7.44 million of net cash, but carried a 22% original-issue discount, an 8% coupon, and $4.88 million of combined day-one losses before considering the additional $2 million interim PIPE. 〔3〕 The filing therefore does not add operating traction or clinical progress; it clarifies that the combined company remains dependent on financing while it develops Lokahi’s therapeutic assets and the CBGM subsidiary.

Bottom line: This is mostly a priced-in capital-structure filing, not a new operating catalyst. The split is cosmetic; the important takeaway is that control has shifted to Lokahi and the combined platform carries meaningful short-term financing pressure.

Original filing on SEC EDGAR

More Glucotrack, Inc. news

Glucotrack reverse split confirms Lokahi control, adds debt detail | GCTK Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.